Piper Jaffray analyst Sean Wieland raised his price target for Tivity Health to $33 from $29 saying the company reported upside to both revenue and profitability, “despite several headwinds.” This is an early indicator that its new consumer marketing strategies are working, Wieland tells investors in a post-earnings research note. The analyst reiterates an Overweight rating on Tivity Health.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.